Healthcare
Universe Pharmaceuticals Inc.(UPC)
Live Price
Offline$2.95
+1.37% today
1Y Change
-25.95%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- -22.4%
- EPS Growth
- +26.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Universe Pharmaceuticals Inc. (UPC) is a Healthcare stock with listed on NASDAQ. The stock last traded around $2.95 and down 26.0% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -22.4%, EPS growth of +26.5%, a dividend yield of 0.0%. What stands out right now is revenue -22.4%, EPS +26.5%, free cash flow +45.3% with operating margin -16.3% and ROIC -4.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UPC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-22.4% vs +7.6% peer median
Operating Margin
Below sector median
-16.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 22, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -22.4% and EPS is at +26.5%, with operating margin around -16.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 22, 2026 | โ | +1.8% | -2.1% | -18.2% |
2024 Apr 30, 2024 | โ | -4.1% | -7.1% | -11.5% |
2024 Feb 9, 2024 | โ | -4.1% | -7.1% | -11.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UPC
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
UPC Max Drawdown
-76.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for UPC and SPY.
Company Overview
Universe Pharmaceuticals Inc.
NASDAQ Global Market
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
- Leadership
- Gang Lai
- IPO Date
- Mar 23, 2021
- Employees
- 225
- Street Address
- No. 265, Jingjiu Avenue
- Mailing
- Ji'An, 343100
- Region
- Ji'An, CN
- Reporting Currency
- USD
- Investor Line
- 86 571 8755 5823
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 7.7
- Price/Sales
- 0.1
- Price/Book
- 0.0
Growth
- Revenue
- -22.4%
- EPS
- +26.5%
- Free Cash Flow
- +45.3%
Profitability
- Gross Margin
- 35.3%
- Operating Margin
- -16.3%
- Net Margin
- -20.6%
- ROE
- -6.6%
- ROIC
- -4.5%
Balance Sheet
- Debt/Equity
- 0.16
- Current Ratio
- 4.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.